Synthesis of 2, 5-Dichloro-N-[2-(Isopropylsulfonyl) Phenyl]-Pyrimidin-4-Amine

化学工业与工程

Chemcial Industry and Engineering

2018, Vol. 35

Issue (5) :7-11 DOI: 10.13353/j.issn.1004.9533.20161097

Current Issue | Next Issue | Archive | Adv Search

<< | >>

Synthesis of 2, 5-Dichloro-N-[2-(Isopropylsulfonyl) Phenyl]-Pyrimidin-4-Amine

Chen Yalin^1,2,3, Li Wei^1,2,3, Zhou Xueqin^1,2,3, Wang Tianyang^1,2,3, Liu Dongzhi^1,2,3

1. School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China;
2. Collaborative Innovation Center of Chemical Science and Engineering, Tianjin 300072, China;
3. Tianjin Engineering Research Center of Functional Fine Chemicals, Tianjin 300072, China

Abstract	Reference	Related Articles

Download: PDF (917KB) HTML () Export: BibTeX or EndNote (RIS) Supporting Info

Abstract 2,5-Dichloro-N-(2-(isopropylsulfonyl) phenyl)-pyrimidin-4-amine was synthesized from 1-(isopropylsulfonyl)-2-nitrobenzene by reaction of reduction and nucleophilic substitution. The target compounds with high purity and high yield were obtained by optimizing the reaction conditions. The structure of the resulting product was confirmed by ¹H-NMR and MS. The process exhibited short reaction time, low cost, high yield, and to a certain extent, in line with the requirements of industrial production.

	Service

	Email this article
	Add to my bookshelf
	Add to citation manager
	Email Alert
	RSS
	Articles by authors
	Chen Yalin
	Li Wei
	Zhou Xueqin
	Wang Tianyang
	Liu Dongzhi

Keywords： 2,5-dichloro-N-[2-(isopropylsulfonyl) phenyl]-pyrimidin-4-amine； anaplastic lymphoma kinase； 2-(isopropylsulfonyl) benzenamine； synthesis

Received 2016-05-10;

About author:

Cite this article:

Chen Yalin, Li Wei, Zhou Xueqin, Wang Tianyang, Liu Dongzhi.Synthesis of 2, 5-Dichloro-N-[2-(Isopropylsulfonyl) Phenyl]-Pyrimidin-4-Amine[J] Chemcial Industry and Engineering, 2018,V35(5): 7-11

[1] Shaw A T, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer[J]. Clinical Cancer Research, 2011, 17(8):2081-2086
[2] Ou S,Bartlett C,Mino-Kenudson M,et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer:A success story to usher in the second decade of molecular targeted therapy in oncology[J]. Oncologist,2012,17(11):1351-1375
[3] Choi Y,Takeuchi K,Soda M,et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer[J]. Cancer Res,2008,68(13):4971-4976
[4] Li Y,Ye X,Liu J,et al. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors[J]. Neoplasia,2011,13(1):1-11
[5] 葛丹丹, 宫平. 色瑞替尼(ceritinib)[J]. 中国药物化学杂志, 2014, (5):420-420 Ge Dandan, Gong Ping. Ceritinib[J]. China Magazine Pharmaceutical Chemistry, 2014, (5):420-420(in chinese)
[6] Shaw A T, Kim D W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. New England Journal of Medicine, 2013, 368(25):2385-2394
[7] Ettinger D,Akerley W,Borghaei H,et al. Non-Small cell lung cancer,version 2. 2013[J]. J Natl Compr Canc Netw, 2013, 11(6):645-653
[8] Stockwell S. FDA approval for zykadia for late-stage lung cancer[J]. Oncology Times, 2014, 36:10
[9] 陈少波, 张厚德. 克唑替尼抗肿瘤的研究进展[J]. 中国现代医生, 2015, (14):156-160 Chen Shaobo, Zhang Houde. Research progress of anti tumor of Crizotinib[J]. Chinese Modern Doctor, 2015, (14):156-160(in chinese)
[10] McDermott U,Iafrate A,Gray N,et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors[J]. Cancer Res, 2008, 68(9):3389-3395
[11] Chen J,Jiang C,Wang S. LDK378:A promising anaplastic lymphoma kinase (ALK) inhibitor[J]. J Med Chem, 2013, 56(14):5673-5674
[12] Galkin A, Melnick J, Kim S, et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK[J]. Proceedings of the National Academy of Sciences, 2007, 104(1):270-275
[13] Garcia-Echeverria C, Kanazawa T, Kawahara E, et al. 2,4-Di(phenylamino)pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders:WO, 2004080980[P]. 2004-09-23
[14] Kwiatkowski N, Jelluma N, Filippakopoulos P, et al. Small-Molecule kinase inhibitors provide insight into Mps1 cell cycle function[J]. Nature Chemical Biology, 2010, 6(5):359-368
[15] Gray N, Zhou W. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith:US, 12/976,980[P]. 2010-12-22
[16] Marsilje T, Pei W, Chen B, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N 2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl) phenyl)-N 4-(2-(isopropylsulfonyl) phenyl) pyrimidine-2, 4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials[J]. Journal of Medicinal Chemistry, 2013, 56(14):5675-5690
[17] 王永珍, 赵砚瑾, 胡文祥, 等. 2,5-二氯-N-[2-(异丙基磺酰基)苯]-4-胺的合成[J]. 昆明理工大学学报,2012, 37:300-304 Wang Yongzhen, Zhao Yanjin, Hu Wenxiang, et al. Synthesis of 2,5-dichloro-N-[2-(isopropylsulfonyl) phenyl]-pyrimidin-4-amine[J]. Journal of Kunming University of Science and Technology, 2012, 37:300-304(in Chinese)
[18] 邓维, 刘磊, 郭庆祥. 铜催化交叉偶联反应研究的新进展[J]. 有机化学, 2004, 24(2):150-165 Deng Wei, Liu Lei, Guo Qingxiang. Recent progress in copper-catalyzed cross-coupling reactions[J]. Chinese Journal of Organic Chemistry, 2004, 24(2):150-165(in Chinese)